<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Mutations in the v-Ki-ras2 Kirsten rat <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homolog (KRAS) play a critical role in <z:e sem="disease" ids="C1516170" disease_type="Neoplastic Process" abbrv="">cancer cell growth</z:e> and resistance to therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Most mutations occur at codons 12 and 13 </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, the presence of any mutant KRas amino acid substitution is a negative predictor of patient response to targeted therapy </plain></SENT>
<SENT sid="3" pm="."><plain>However, in <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>), the evidence that KRAS mutation is a predictive factor is conflicting </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We used data from a molecularly targeted clinical trial for 215 patients with tissues available out of 268 evaluable patients with refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> to examine associations between specific mutant KRas proteins and progression-free survival and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> gene expression </plain></SENT>
<SENT sid="5" pm="."><plain>Transcriptome microarray studies of patient <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples and reverse-phase protein array studies of a panel of 67 NSCLC cell lines with known substitutions in KRas and in immortalized human bronchial epithelial cells stably expressing different mutant KRas proteins were used to investigate signaling pathway activation </plain></SENT>
<SENT sid="6" pm="."><plain>Molecular modeling was used to study the conformations of <z:mp ids='MP_0002169'>wild-type</z:mp> and mutant KRas proteins </plain></SENT>
<SENT sid="7" pm="."><plain>Kaplan-Meier curves and Cox regression were used to analyze survival data </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> statistical tests were two-sided </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: Patients whose <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had either mutant KRas-Gly12Cys or mutant KRas-Gly12Val had worse progression-free survival compared with patients whose <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had other mutant KRas proteins or <z:mp ids='MP_0002169'>wild-type</z:mp> KRas (P = .046, median survival = 1.84 months) compared with <z:hpo ids='HP_0000001'>all</z:hpo> other mutant KRas (median survival = 3.35 months) or <z:mp ids='MP_0002169'>wild-type</z:mp> KRas (median survival = 1.95 months) </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> cell lines with mutant KRas-Gly12Asp had activated phosphatidylinositol 3-kinase (PI-3-K) and <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling, whereas those with mutant KRas-Gly12Cys or mutant KRas-Gly12Val had activated Ral signaling and decreased growth factor-dependent Akt activation </plain></SENT>
<SENT sid="11" pm="."><plain>Molecular modeling studies showed that different conformations imposed by mutant KRas may lead to altered association with downstream signaling transducers </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Not <z:hpo ids='HP_0000001'>all</z:hpo> mutant KRas proteins affect patient survival or downstream signaling in a similar way </plain></SENT>
<SENT sid="13" pm="."><plain>The <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> behavior of mutant KRas proteins implies that therapeutic interventions may need to take into account the specific mutant KRas expressed by the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
</text></document>